Lv2
130 积分 2024-03-06 加入
子宫内膜癌分子分型临床应用中国专家共识（2024年版）
2个月前
已完结
Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: results from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study
3个月前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
4个月前
已完结
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
4个月前
已完结
Evaluation of Heavy-Chain C-Terminal Deletion on Product Quality and Pharmacokinetics of Monoclonal Antibodies
5个月前
已完结
我国2019年至2021年审评建议批准上市创新药的审评和临床试验现场核查情况分析
6个月前
已完结
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
8个月前
已完结
Quality by design: Impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody
8个月前
已完结
皖公网安备34019202002308
